Introduction
The mammalian hematopoietic system is subject to a consistent renewal during the life span of an individual. Inherited and acquired hematopoietic failure can be caused by diseases such as myelodysplastic syndrome, acute myeloid leukemia, and Fanconi anemia (1) (2) (3) , as well as a consequence of chemotherapy treatment or accidental over-dose exposure to radiation and other toxic agents (4) (5) (6) (7) . Depleting the host bone marrow (BM) hematopoietic cells before allogeneic hematopoietic stem cell (HSC) transplantation is commonly used to treat a wide array of malignancies including multiple myeloma, leukemias, lymphomas, and some solid tumors (8) (9) (10) .
Understanding the molecular factors that modulate hematopoietic recovery is essential to improve the outcomes of these diseases and treatments.
Lysine methylation plays an important role in diverse cellular processes to regulate chromatin structures, genome stability, and fate determination of stem cells, etc (11) (12) (13) (14) (15) (16) (17) (18) (19) . Many lysine methyltransferases harbor a Su(var)3-9-Enhancer of zeste-Trithorax (SET) domain, which is responsible for transferring a methyl group from S-adenosylmethionine to lysine residues. The human genome encodes an estimated of 58 SET domain methyltransferases (20) . Although most of the SET domain proteins have documented histone modifying activity, the SETD6 group of SET proteins (including SETD6, SETD3 and SETD4) represents a distinct class of non-histone methyltransferases (20) , and they share a similar substrate-binding domain resembling that of the plant Rubisco methyltransferase (21) (22) (23) (24) (25) (26) (27) . SETD6 methylates p65 (RelA)(24,28), and other non-histone proteins(29-31). SETD3 was initially reported to methylate histones(32,33), but recently found to a histidine residue in b-actin (25, 26, 34) . However, little is known about the function of mammalian SETD4.
The brine shrimp Artemia Parthenogenetica SETD4 was initially suggested to play a role in methylating histone H4K20 and H3K79 (21) , and the human SETD4 protein may have the same activity (35). However, another report failed to identify these sites as SETD4 substrates, and instead suggested H3K4 as the substrate of SETD4 in macrophages (36). Emerging evidence suggests that SETD4 may have an oncogenic activity(37-39). According to the TCGA database, oncogenic fusion of SETD4 was found to be with TMPRSS2 in prostate cancer, with FTCD in invasive ductal carcinoma, with KIAA1958 in serous ovarian cancer, and with B4Galt6 in lung squamous cancer. SETD4 was highly expressed in the quiescent breast cancer stem cell subpopulation of MCF7 cells(35), and an induced Setd4 deletion in adult mice delayed the radiationinduced T-lymphoma development in mice(40).
In this study, we found that induced Setd4 knockout in adult mice improved the hematopoietic recovery after total body irradiation (TBI). Interestingly, the improved recovery was not associated with a resistance of the Setd4 deficient HSCs to radiation, rather the Setd4 deficient HSC were actually more sensitive to radiation than wild type HSC in vivo. However, Setd4 deficient mice were more receptive to HSC transplantation from wild type donors, and that Setd4 deficient HSCs had a repopulating advantage in recipient mice after transplantation. These results underscore the unique mode by which Setd4 regulates hematopoiesis and implied that Setd4 inhibition may not only improve the competence of donor HSCs but also the ability of the recipient BM to receive the transplantation. Setd4 deletion(40). Mice were temporarily restrained in a disk-shaped container and whole-body irradiated with γ-rays.
Materials and Methods

Detailed materials and methods can be found in the Supplemental
Analysis of BM and peripheral blood cells
BM single-cell suspensions were counted to determine the total number of cells. Then, aliquots were stained for surface markers to determine the relative abundance of each cell types (41) . The sources of antibodies are listed in Tables S2 and S3 . For BM transplantation, a given number of sorted donor Lin-cells were transplanted into lethally irradiated recipient mice. Blood was collected to monitor the success of the transplantation based on the donor CD45.1 or CD45.2 congenic markers.
Statistics
Statistical analyses were performed using Prism GraphPad, including Student's t-test and Logrank (Mantel-Cox) test.
Results
Deletion of Setd4 protects mice from ionizing radiation (IR) induced BM failure
To avoid any potential impact of a constitutive Setd4 deletion on the embryonic and early postnatal development of mice, the Tam-inducible we found that Setd4 Δ/Δ mice survived significantly better than the mice treated with Oil when exposed to 8 Gy TBI (Fig. 1A) . When the mice were exposed to a higher dose of 9 Gy (Fig. 1B) did not alter the overall survival of the mice (Fig. 1C) . It is interesting that the improved survival of the Setd4 Δ/Δ mice was similar to the level of p53 Δ/Δ mice, but co-deletion of p53 and Setd4 had an additive effect and better protected the mice from irradiation (Fig. S1 ).
It is well established in the radiation biology field that radiation-induced BM failure often results in death within 30 days and mostly between 2-3 weeks. The results in Fig. 1A Gy TBI, and all mice died within 10 days post TBI (Fig. S3) , which is typical of radiation induced GI syndrome. The similar sensitivity of these mice in both groups suggested that there was no effect of Setd4 loss in protecting the mice from radiation induced GI syndrome.
Setd4 deletion promotes BM recovery
Since the deletion of Setd4 protected mice from the fatality of radiation induced hematopoietic syndrome, we hypothesized that Setd4 may modulate BM recovery from radiation damage. To test 
Enhanced splenic erythropoiesis in Setd4 deficient mice post TBI
In adult rodents, erythropoiesis in peripheral lymphoid organs occurs to support the animals when BM repopulation is impaired (45) . During the course of the study, we noticed that Setd4 Δ/Δ mice had enlarged spleens more frequently than control mice ( Fig. 3A-B ). This prompted us to investigate whether there was any effect of Setd4 loss on splenic erythropoiesis. Based on the stages of erythroid maturation ( Fig. 3C ), we analyzed cell surface markers CD71 and Ter119, which are commonly used to define the maturation stages of erythroid progenitor cells (46) . We It is generally believed that both the fitness of the stem and progenitor cells in the hematopoiesis hierarchy, and the regulatory function of the BM microenvironment niche contribute to the recovery from the hematopoietic failure (7, 47) . To understand the mechanism(s) by which Setd4 deficiency conferred an enhanced BM recovery, we first investigated whether Setd4 deletion confers radiation resistance to the stem and progenitor cells in the hematopoietic hierarchy using two independent approaches.
First, we measured the role of Setd4 in the sensitivity of hematopoietic stem and progenitor cells ( To allow the transplanted LT-HSCs to replenish the entire hematopoiesis hierarchy(49), the recipient chimeric mice were kept for 16 weeks, and then treated with TBI (8Gy). Surprisingly, the mice transplanted with Setd4 Δ/Δ HSCs actually were more sensitive than the mice transplanted with the Setd4 flox/flox HSCs (Fig. 4D ). This finding is contradictory to our initial prediction that the mice, which did not explain why the Setd4 Δ/Δ mice were more resistant to radiation induced hematopoietic syndrome than the Setd4 flox/flox mice.
To verify the above findings, we carried out a competitive transplantation assays as outlined in Fig. 5A . First, we depleted the BM of wild-type recipient mice (CD45.1) as described previously (48 To assess the long-term fitness of the BM cells, the above mice were sacrificed 28 weeks after irradiation (or 48 weeks after the initial transplantation) and lineage analysis was performed on their BM cells as described in Fig. 2 and S4. As shown in Fig. 5D 
Setd4 deletion confers an improved BM microenvironment to support HSC transplantation
Collectively, data from the BM transplantation assays (Fig. 4 and 5 
Discussion
In this study, we developed the first Setd4-knockout mouse model to directly identify the function of SETD4 in mammalians, and surprisingly found that Setd4-deficient mice were more resistant to radiation-induced hematopoietic syndrome. Interestingly, Setd4 deletion conferred a radiosensitivity to the HSCs in vivo, but the non-irradiated Setd4 deficient HSCs had an advantage over wild type HSCs in recipient mice, and the BM niches of the Setd4-deficient recipient mice had an enhanced ability to engraft transplanted HSCs. Furthermore, there was an enhanced splenic erythropoiesis in Setd4 deficient mice. These novel findings suggest a unique mode of action by which Setd4 modulates the recovery from BM failure and underscores the importance of the BM niche in the recovery from hematopoietic failure.
Given that BM injury is a major adverse side effect of anticancer therapy and excessive exposure to radiation, it is possible that inhibition of Setd4 during these circumstances may be beneficial to the recovery of the BM. Based on our findings, it is foreseeable that inhibition of Setd4 would: 1) sensitize cells of the HSC lineage in the host to BM depletion, 2) make the host BM niche more amenable to receive allogeneic transplantation, and 3) improve the competence of the donor HSCs. Thus, Setd4 would potentially be an attractive target for inhibition to help condition the BM before allogeneic transplantation, a strategy used to treat widely disseminated malignancies and some solid tumors (8) (9) (10) .
It is well known that the overall function of the hematopoietic system is both intrinsically regulated by the HSCs and their progenies, as well as by the BM niche nurturing the HSCs. One striking finding of our study is that the Setd4 deficient HSCs are actually more sensitive to irradiation, but the BM niche of the same Setd4 deficient mice is more receptive to the engraftment of HSC upon transplantation. However, the overall consequence of these confounding effects was an improved recovery from radiation induced hematopoietic failure. This finding underscores the importance of the BM niche in the overall function of the hematopoietic system.
It should be noted that our results also suggested that the improved recovery of Setd4 deficient mice is independent of p53 deletion, and Setd4 loss further enhanced the survival of p53-deficient mice post IR (Fig. S1 ). Pharmacological inhibition of p53 has been proposed to protect individuals from acute BM injury and attenuate the development of radiation-related blood cancer (50) .
Similarly, it is foreseeable that targeting Setd4 may represent another strategy to protect BM from radiation and radiation-induced lymphomagenesis.
The mammalian SETD4 is largely an orphan methyl-transferase since no physiological substrate of mammalian SETD4 has been reported. Several preliminary reports have suggested a potentially oncogenic activity of mammalian SETD4(37-39), and oncogenic fusions of SETD4 had been reported in TCGA database. The conditional Setd4 deletion did not significantly change spontaneous tumor formation(40), which is in an agreement with these preliminary reports. Clearly, this study has only just begun to reveal the function of mammalian SETD4, and additional studies would need to be performed to further understand SETD4 activities in mammalians.
In summary, our studies revealed a critical role of Setd4 in maintaining hematopoiesis, suggesting that Setd4 inhibition might be an attractive strategy to mitigate radiation-induced BM injury, and improve the outcome of allogeneic HSC transplantation after TBI for patients with widely disseminated malignancies. Future studies will be needed to identify physiological SETD4 substrates and to elucidate the regulatory mechanisms of SETD4 expression. In all panels, each dot represents the data from an independent mouse, and none-irradiated mice are shown as day 0. *: p<0.05, **: P<0.01. Table S5 for the specific number of mice used in each time point). The curves were fit by nonlinear regression. Chromo-E
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